COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03951623
Recruitment Status : Recruiting
First Posted : May 15, 2019
Last Update Posted : June 16, 2020
Information provided by (Responsible Party):
Hutchison Medipharma Limited

Brief Summary:
This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. The trial has two parts: dose escalation (stage 1) and dose expansion (stage 2). No cross-over treatment will be allowed during the study.

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia (ITP) Drug: HMPL-523 Drug: Placebo Phase 1

Detailed Description:
Approximate 51 to 60 patients will be enrolled in dose escalation (3 cohorts, 8 subjects each with the ratio of 3:1 vs Placebo) and dose expansion (1 cohort, 27-36 subjects with the ratio of 2:1 vs Placebo).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523, a Syk Inhibitor in Adult Patients of Immune Thrombocytopenia: a Randomized, Double Blinded, Placebo Controlled Phase Ib Study
Actual Study Start Date : May 30, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Arm Intervention/treatment
Active Comparator: treatment arm
Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks.
Drug: HMPL-523
HMPL-523 will be oral administrated once daily for 8 weeks.

Placebo Comparator: placebo arm
Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks.
Drug: Placebo
HMPL-523 matching placebo will be oral administrated once daily for 8 weeks.

Primary Outcome Measures :
  1. Number of Participants with any Adverse Event [ Time Frame: From first dose to within 28 days after the last dose ]
    Adverse Events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: Day 15, 16, 29, 43 and 47 in dose escalation phase and Day 15, 29, 43 and 57 in dose expansion phase ]
    Maximum plasma concentration (Cmax)

  2. Area under the concentration-time curve in a selected time interval (AUC0-t) [ Time Frame: Day 15, 16, 29, 43 and 47 in dose escalation phase and Day 15, 29, 43 and 57 in dose expansion phase ]
    Area under the concentration-time curve in a selected time interval (AUC0-t)

  3. Rate of Clinical Remission [ Time Frame: Day 1 to 8 weeks treatment ]
    Rate of Clinical Remission was defined as the proportion of patients who have platelet ≥30×10^9/L at week 8 and increased ≥20×10^9/L vs baseline without anti-ITP emergency treatment during the study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent form
  2. 18~75 years old male of female
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  4. Diagnosed immune thrombocytopenia before randomization with persist platelet decrease for more than 6 months.
  5. Patients with refractory or relapsed ITP who have been treated with 1st line anti-ITP regimen or have experienced splenectomy.
  6. Relative stable disease with World Health Organization (WHO) bleeding score of 0-1 and no rescue treatment needed within 2 weeks based on investigator's judgment.

Exclusion Criteria:

  1. Patients with secondary thrombocytopenia or patients have other auto immune diseases who need long term steroids or immunosuppressants treatment.
  2. Patients with Myelofibrosis, Myelodysplastic syndrome, Aplastic anemia, or other hematologic malignancies.
  3. Have splenectomy within 12 weeks before randomization
  4. Patients with resistant hypertension (Systolic blood pressure ≥140 mmHg or Diastolic blood pressure ≥90 mmHg)
  5. Prior anti-ITP emergency treatment within 2 weeks before randomization.
  6. Prior anti-ITP treatment within 4 weeks before randomization except for stable dose steroids, including but not limited to Thrombopoietin, thrombopoietin receptor agonist, azathioprine, danazol, cyclosporine A and mycophenolate mofetil.
  7. Any condition requiring anti-coagulant therapy or the regular use of any medication having effluence to Platelet function.
  8. Exposure to Rituximab 14 weeks prior to randomization.
  9. Use of strong cytochrome P450 isoform 3A inhibitors and inducers and drugs metabolized by cytochrome P450 isoform 3A, cytochrome P450 isoform 2B6, and cytochrome P450 isoform 1A2, and are identified as narrow therapeutic drugs within 7 days or 3 half-lives, whichever is longer, prior to initiation of study treatment.
  10. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (eg, fostamatinib)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03951623

Layout table for location contacts
Contact: jiayi Mai 086-021-20673063

Layout table for location information
China, Tianjin
Blood diseases hospital, Chinese academy of medical university Recruiting
Tianjin, Tianjin, China, 300000
Contact: Renchi Yang   
Sponsors and Collaborators
Hutchison Medipharma Limited
Layout table for investigator information
Study Director: Rongjun Liu Hutchison MediPharma
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited Identifier: NCT03951623    
Other Study ID Numbers: 2018-523-00CH1
First Posted: May 15, 2019    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hutchison Medipharma Limited:
syk inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Immune System Diseases
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms